Pembrolizumab-chemotherapy for advanced oesophageal cancer

被引：0
|
作者：
Gil, Ziv [1 ,2 ]
Billan, Salem [3 ]
机构：
[1] Israel Inst Technol, Head & Neck Surg Unit, Rambam Hlth Care Campus, IL-31096 Haifa, Israel
[2] Israel Inst Technol, Head & Neck Ctr, Rambam Hlth Care Campus, IL-31096 Haifa, Israel
[3] Israel Inst Technol, Dept Oncol & Radiat, Head & Neck Ctr, Rambam Hlth Care Campus, IL-31096 Haifa, Israel
来源：
LANCET | 2021年 / 398卷 / 10302期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：726 / 727
页数：2
相关论文
共 50 条
  • [21] Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer
    Davidson, Michael
    Chau, Ian
    Cunningham, David
    Khabra, Komel
    Iveson, Timothy
    Hickish, Tamas
    Seymour, Matthew
    Starling, Naureen
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2017, 9 (08) : 333 - 340
  • [22] Advanced Esophageal Cancer: Pembrolizumab plus Chemotherapy as First-line Therapy
    Franke, Katharina
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2021, 59 (12): : 1255 - +
  • [23] A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
    Weiss, Glen J.
    Waypa, Jordan
    Blaydorn, Lisa
    Coats, Jessica
    McGahey, Kayla
    Sangal, Ashish
    Niu, Jiaxin
    Lynch, Cynthia A.
    Farley, John H.
    Khemka, Vivek
    BRITISH JOURNAL OF CANCER, 2017, 117 (01) : 33 - 40
  • [24] A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
    Glen J Weiss
    Jordan Waypa
    Lisa Blaydorn
    Jessica Coats
    Kayla McGahey
    Ashish Sangal
    Jiaxin Niu
    Cynthia A Lynch
    John H Farley
    Vivek Khemka
    British Journal of Cancer, 2017, 117 : 33 - 40
  • [25] Clinical Impact of Early Tumour Shrinkage in Metastatic or Unresectable Oesophageal Cancer Treated with Pembrolizumab plus Chemotherapy
    Sugase, Takahito
    Kanemura, Takashi
    Takeoka, Tomohira
    Matsuura, Norihiro
    Masuike, Yasunori
    Shinno, Naoki
    Hara, Hisashi
    Omori, Takeshi
    Kitakaze, Masatoshi
    Kubo, Masahiko
    Mukai, Yosuke
    Sueda, Toshinori
    Hasegawa, Shinichiro
    Akita, Hirofumi
    Nishimura, Junichi
    Wada, Hiroshi
    Yasui, Masayoshi
    Miyata, Hiroshi
    ONCOLOGY, 2024, 102 (06) : 484 - 493
  • [26] Pembrolizumab plus Chemotherapie als Erstlinientherapie beim fortgeschrittenen Ösophaguskarzinom (KEYNOTE-590)Pembrolizumab plus chemotherapy as first-line treatment in advanced oesophageal cancer (KEYNOTE-590)
    Milan Hartmann
    Thomas Zander
    Hakan Alakus
    Der Onkologe, 2022, 28 (5): : 436 - 437
  • [27] Oesophageal preservation in locally advanced oesophageal cancer
    Ajani, Jaffer A.
    Bhutani, Manoop S.
    Swisher, Stephen G.
    LANCET ONCOLOGY, 2018, 19 (09): : E430 - E430
  • [28] Pembrolizumab alone or in combination with chemotherapy versus chemotherapy for advanced gastric cancer: A cost-effectiveness analysis
    Lang, Yitian
    Lin, Yan
    Li, Dan
    Liu, Jiyong
    Liu, Xiaoyan
    CANCER MEDICINE, 2023, 12 (18): : 18447 - 18459
  • [29] Oesophageal cancer: preoperative chemotherapy
    Chong, G
    Cunningham, D
    ANNALS OF ONCOLOGY, 2004, 15 : 87 - 91
  • [30] Oesophageal cancer: chemotherapy first
    不详
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (12) : 1557 - 1557
12345